Structure Therapeutics (NASDAQ:GPCR) Sets New 1-Year Low – Here’s What Happened

Structure Therapeutics Inc. (NASDAQ:GPCR)’s share price reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $28.32 and last traded at $28.41, with a volume of 74570 shares. The stock had previously closed at $31.48.

Wall Street Analyst Weigh In

Several equities analysts have commented on GPCR shares. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a report on Thursday. JMP Securities reiterated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday. Finally, Morgan Stanley started coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $86.50.

Structure Therapeutics Trading Up 7.4 %

The business has a fifty day moving average price of $35.53 and a 200 day moving average price of $39.03. The firm has a market cap of $1.72 billion, a PE ratio of -40.50 and a beta of -3.41.

Institutional Trading of Structure Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. acquired a new stake in Structure Therapeutics during the 2nd quarter worth $6,489,000. Natixis Advisors LLC lifted its holdings in shares of Structure Therapeutics by 29.4% in the 2nd quarter. Natixis Advisors LLC now owns 19,005 shares of the company’s stock valued at $746,000 after purchasing an additional 4,321 shares during the last quarter. Gilbert & Cook Inc. acquired a new stake in shares of Structure Therapeutics in the 2nd quarter valued at about $229,000. TD Asset Management Inc increased its position in Structure Therapeutics by 47.9% during the second quarter. TD Asset Management Inc now owns 211,590 shares of the company’s stock worth $8,309,000 after buying an additional 68,490 shares during the period. Finally, Pier Capital LLC lifted its stake in Structure Therapeutics by 3.7% in the second quarter. Pier Capital LLC now owns 101,204 shares of the company’s stock valued at $3,974,000 after buying an additional 3,647 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.